Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR 931.45
-4.30 (-0.46%)
At close: Dec 5, 2025
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 61.23B INR in the quarter ending September 30, 2025, with 16.92% growth. This brings the company's revenue in the last twelve months to 244.94B, up 14.01% year-over-year. In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B with 18.90% growth.
Revenue (ttm)
244.94B
Revenue Growth
+14.01%
P/S Ratio
3.83
Revenue / Employee
8.77M
Employees
27,917
Market Cap
937.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Divi's Laboratories | 100.29B |
| Cipla | 279.66B |
| Apollo Hospitals Enterprise | 232.65B |
| Mankind Pharma | 135.46B |
| Aurobindo Pharma | 325.14B |
| Alkem Laboratories | 138.90B |
| Fortis Healthcare | 84.37B |
Zydus Lifesciences News
- 2 days ago - Zydus Lifesciences receives EIR from USFDA for the injectable facility at Jarod - Business Upturn
- 8 days ago - Top stocks to watch today, November 28: Adani Enterprises, Wipro, TCS, Tata Technologies, Zydus Lifesciences and more - Business Upturn
- 8 days ago - Zydus Lifesciences gets USFDA Tentative nod for Empagliflozin and Linagliptin tablets - Business Upturn
- 10 days ago - Zydus Lifesciences signs exclusive licensing agreement with RK Pharma for novel oncology supportive care injectable - Business Upturn
- 10 days ago - Top stocks to watch today, November 26: NCC, Zydus Lifesciences, UBL, Waaree Energies, NELCO and more - Business Upturn
- 10 days ago - Top stocks to watch on November 26, 2025: NCC, Zen Technologies, Zydus Lifesciences, Bharti Airtel, HCL Tech, ACS Technologies in focus today - Business Upturn
- 22 days ago - Zydus Lifesciences secures USFDA approval for Leuprolide Acetate Injection - Business Upturn
- 23 days ago - Zydus Lifesciences receives USFDA tentative approval for Diroximel Fumarate capsule, 231 mg - Business Upturn